Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 92% unadjusted Improvement Relative Risk Hospitalization 12% Oku et al. HCQ for COVID-19 PrEP Is pre-exposure prophylaxis with HCQ beneficial for COVID-19? Retrospective 220 patients in Japan (June 2020 - June 2021) Lower hospitalization with HCQ (not stat. sig., p=0.34) Oku et al., Modern Rheumatology, doi:10.1093/mr/roac104 Favors HCQ Favors control
Risk factors for hospitalization or mortality for COVID-19 in patients with rheumatic diseases: Results of a nation-wide JCR COVID-19 registry in Japan
Oku et al., Modern Rheumatology, doi:10.1093/mr/roac104
Oku et al., Risk factors for hospitalization or mortality for COVID-19 in patients with rheumatic diseases: Results of a.., Modern Rheumatology, doi:10.1093/mr/roac104
Sep 2022   Source   PDF  
  All Studies   Meta
Retrospecttive 220 COVID-19 patients with rheumatic disease in Japan, showing lower mortality and hospitalization with HCQ prophylaxis, without statistical significance.
risk of death, 92.2% lower, RR 0.08, p = 1.00, treatment 0 of 14 (0.0%), control 11 of 206 (5.3%), NNT 19, unadjusted, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of hospitalization, 11.5% lower, RR 0.88, p = 0.34, treatment 9 of 14 (64.3%), control 177 of 206 (85.9%), NNT 4.6, adjusted per study, odds ratio converted to relative risk, multivariable.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Oku et al., 6 Sep 2022, retrospective, Japan, peer-reviewed, 8 authors, study period 3 June, 2020 - 30 June, 2021.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: MORH-D-22-00049 Received: 20-Jan-2022; Accepted: 4-Aug-2022 Original Article Risk factors for hospitalization or mortality for COVID-19 in patients with rheumatic diseases: Results of a nation-wide JCR COVID-19 registry in Japan Okamoto5), Tatsuya Atsumi6), Tsutomu Takeuchi4) and The member of the JCR-COVID19 patient registry team 1) Department of Rheumatology and Infectious Diseases, Kitasato University, Kanagawa, Japan 2) Department of Internal Medicine, Kyushu University Beppu Hospital, Oita, Japan 3) Department of Rheumatology and Nephrology, Chubu Rosai Hospital, Aichi, Japan 4) Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan 5) Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Osaka, Japan 6) Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido, Japan *Kenji Oku and Yasutaka Kimoto contributed equally to this article. Corresponding author: Takahiko Horiuchi, Department of Internal Medicine, Kyushu University Beppu Hospital, Oita, Japan Email: ABSTRACT Background: The incidence and prognosis of COVID-19 and rheumatic disease vary among ethnicities and regions. COVID-19 outcomes in rheumatic disease patients remain unclear, especially in the Asia-Pacific region. This study aimed to clarify the demographic and clinical factors that may influence COVID-19 prognosis in rheumatic disease patients. © Japan College of Rheumatology 2022. Published by Oxford University Press. Kenji Oku1)*, Yasutaka Kimoto2)*, Takahiko Horiuchi2), Mari Yamamoto3), Yasushi Kondo4), Masashi Methods: This was a case series of patients registered with the COVID-19 national registry of Japan College of Rheumatology between June 3, 2020, and June 30, 2021. Multivariable logistic regression was used to estimate the risk of hospitalization or death. Age, sex, smoking status, rheumatic disease diagnosis, comorbidities, and rheumatic disease medications are taken immediately before infection was analyzed. Results: A total of 220 patients from 55 institutions in Japan were included in the study, among whom 186 and mainly comprised glucocorticoids, favipiravir, remdesivir, and tocilizumab. In the multiple logistic regression model, older age and a history of hypertension were associated with hospitalization, while older age was associated with mortality. No specific treatment was correlated with mortality or hospitalization by the multi-variate analysis. Conclusions: Older age and hypertension were associated with a poor prognosis in Japanese COVID-19 patients with CTD. Factors not directly related to CTD were closely associated with the prognosis. Keywords: COVID-19, Japan, Rheumatic disease, SARS-CoV2 In December 2019, the report of pneumonia of an unknown cause found in Wuhan, Hubei Province, China spread out to the world. The infection was found to be caused by a novel coronavirus, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), and the disease was named Coronavirus Disease 2019 (COVID-19). COVID-19 spread rapidly all over the world, and on March 11, 2020, the WHO declared a pandemic. In Japan, the first case was reported on January 15, 2021, and by June 2021, 0.8 million people (6.7% of the..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop